RPG Life Sciences Q3 FY26: Revenue up by 4.2% Y-o-Y and EBITDA margin at 24.0%

RPG Life Sciences Limited has announced its financial results for the third quarter ended 31 December, 2025. The company recorded a 4.2% Y-o-Y increase in revenue, along with a healthy EBITDA margin of 24.0%. For 9M FY26, revenue grew 4.0% Y-o-Y. The Domestic Formulations business delivered growth ahead of the Indian Pharmaceutical Market, recording a growth of 11.8% in 9M FY26 compared to the IPM growth of 8.2%, driven by strong brand performance, improved field effectiveness, and sharper customer engagement. The company aims to build a future-ready pharmaceutical enterprise that is resilient, innovation-led, and people-first, creating sustainable value for patients, partners, and stakeholders.